Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions

Blood

Volumn 95, Issue 4, 2000, Pages 1214-1221

  Porter, David L ^a   Collins Jr , Robert H ^b   Hardy, Christine ^b   Kernan, Nancy A ^b   Drobyski, William R ^b   Giralt, Sergio ^b   Flowers, Mary E D ^b   Casper, James ^b   Leahey, Ann ^b   Parker, Pablo ^b   Mick, Rosemarie ^b   Bate Boyle, Bev ^b   King, Roberta ^b   Antin, Joseph H ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; DISEASE ASSOCIATION; DONOR; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA; LEUKOCYTE TRANSFUSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; REMISSION; SURVIVAL; TREATMENT INDICATION;

ANALYSIS OF VARIANCE; BONE MARROW TRANSPLANTATION; CONFIDENCE INTERVALS; DATABASES; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; LEUKOCYTE TRANSFUSION; LIVING DONORS; MALE; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0034651931     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Porter D, Roth M, McGarigle C, Ferrara J, Antin J. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994;330:100-106.
2. Bar B, Schattenberg A, Mensink E, Geurts Van Kessel A, et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol. 1993;11:513-519.
3. Collins R, Shpilberg O, Drobyski W, Porter D, Giralt S, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997; 15:433-444.
4. Drobyski W, Keever C, Roth M, Koethe S. Hanson G, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood. 1993;82:2310-2318.
5. Helg C, Roux E, Beris P, Cabrol C, Wacker P, et al. Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplant. 1993;12: 125-129.
6. Hertenstein B, Wiesneth M, Novotny J, Bunjes D, Stefanic M, et al. Interferon-A and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transplantation. 1993; 56:1114-1118.
7. Kolb H, Mittermuller J, Clemm C, Holler E, Ledderose G, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990; 76:2462-2465.
8. Kolb H, Schattenberg A, Goldman J, Hertenstein B, Jacobsen N, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041-2050.
9. Mackinnon S, Papadopoulos E, Carabasi M, Reich L, Collins N, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 1995;86:1261-1268.
10. van Rhee F, Lin F, Cullis J, Spencer A, Cross N, Chase A, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case forgiving donor leukocyte transfusions before the onset of hematologie relapse. Blood. 1994;83:3377-3383.
11. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood. 1996;87:2195-2204.
12. Porter D, Roth M, Lee S, McGarigle C. Ferrara J, Antin J. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1996;18:975-980.
13. Szer J, Grigg A, Phillipos G, Sheridan W. Donor leucocyte infusions after chemotherapy tor patients relapsing with acute leukaemia following allogeneic BMT. Bone Marrow Transplant. 1993; 11:109-111.
14. Porter D, Antin J. Adoptive immunotherapy in bone marrow transplantation. In: Burakoff S, Deeg H, Ferrara J, eds. Graft-Versus-Host Disease. New York, NY: Marcel Dekker; 1997:733-754,
15. Mrsic M, Horowitz M, Atkinson K, Biggs J, Champlin R et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant. 1992;9:269-275.
16. Radich J, Sanders J, Buckner C, Martin P, Petersen F, et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol. 1993 ;11:304-313.
17. van Rhee R, Savage D, Blackwell J, Orchard K. Dazzi F, et al. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant. 1998;21:1055-1061.
18. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
19. Kalbfleish J, Prentice R. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons; 1980.
20. Cox D, Oakes D. Analysis of Survival Data. London: Chapman and Hall; 1984.
21. Neter J, Wasserman W, Kutner M. Applied Linear Statistical Models. Burr Ridge: Richard D. Irwin, Inc; 1990.
22. Cox D: Analysis of Binary Data. London: Methuen and Co; 1970.
23. SAS/STAT User's Guide. 6th ed. Cary, NC: SAS Institute, Inc; 1990.
24. Delage R, Soiffer R, Dear K, Ritz J. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood. 1991;78:2759-2767.
25. Roth M, Antin J, Ash R, Terry V, Gotlieb M, et al. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood. 1992;79:276-282.
26. Radich J, Gehly G, Gooley T, Bryant E, Clift R, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood. 1995;85:2632-2638.
27. van Rhee F, Lin F, Cross NC, Reid CD, Lakhani AK, et al. Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia. Bone Marrow Transplant. 1994;14:609-612.
28. Barrett A, Locatelli F, Treleaven J, et al. Second transplants for leukemic relapse after bone marrow transplantation: high early mortality but favorable effect of chronic GVHD on continued remission. Br J Haematol. 1991;78:567-574.
29. Mehta J, Powles R, Treleaven J, Horton C, Meller S, Pinkerton C, Singhal S. Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy. Bone Marrow Transplant. 1997; 19:709-719.
30. Hessner M, Enean D, Casper J. Horowitz M, Keever-Taylor C, et al. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T cell depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood. 1995;86:3987-3996.
31. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995;86:4337-4343.
32. Alyea E, Soiffer R, Canning C, Neuberg D, Schlossman R, et al. Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 1998;91:3671-3680.
33. Barrett A, Mavroudis D, Molldrem J, Read E, Carter C, et al. Optimizing the dose and timing of lymphocyte add-back in T-cell depleted BMT between HLA-identical siblings [abstract]. Blood. 1996;88:460a.
34. Small T, Papadopoulos E, Boulad F. Black P, Castro-Malaspina H, et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood. 1999;93:467-480.